Introduction#
Cosmos Health Inc. has announced an exciting projection for its Cur18 product, expecting it to generate over $2.5 million in additional revenue in the United States within the next 12 to 18 months. This projection is significant for the company, which currently has a market capitalization of $18.15 million and reported $65.27 million in revenue over the past year, reflecting a 20% growth.
About Cur18#
Cur18 is a dietary supplement based on curcumin, a compound found in turmeric known for its potential health benefits. It is part of the company’s "18 Series" of nutraceutical products. Cur18 is formulated with a unique ingredient that has been studied in clinical research, placing it within the growing U.S. market for turmeric and curcumin supplements.
Revenue Projections#
The anticipated revenue from Cur18 is based on internal estimates that consider pricing, expected sales volumes, and the gradual growth of distribution channels. The company emphasizes that these projections depend on successfully implementing its commercialization strategy.
Market Strategy and Company Overview#
Cosmos Health plans to initially market Cur18 through direct-to-consumer online sales, with the possibility of expanding into select retail locations in the future. The CEO, Greg Siokas, highlighted that Cur18 is a crucial step in the company’s strategy to enter a well-established market with a scientifically supported product.
In addition to Cur18, Cosmos Health recently reported record revenue of $65.27 million for the year ending December 31, 2025, marking a 20% increase from the previous year. The company also plans to launch its Liv18 liver health supplement, expecting over $5 million in annual revenue starting in April 2026. Furthermore, Cosmos Health is enhancing its operations by integrating artificial intelligence to improve efficiency and customer engagement.